AKT1 and lung carcinoma: Additionally, for the targeted drug of lung cancer, Gefitinib had a favorable response in the low-risk group (Figure 9E) and so did AKT inhibitor VIII (Figure 9F), suggesting that targeted therapy may provide benefit to these patients.